A proportion of patients who present with gastric cancer have disseminated disease that cannot be detected by currently available methods (Koga et al., 1987; Maehara et al., 1992) . Despite radical excision of the primary tumour, almost half the number of patients with gastric cancer will die from progression of a distant tumour. Prognostic criteria, i.e., the depth of invasion, tissue differentiation, tumour size and the spread to lymph nodes have been used in an attempt to identify a group of patients who have local disease but are at high risk of developing metastases (Maehara et al., 1991; Moriguchi et al., 1992) . In these patients, the principal cause of death is metastasis occurring early in tumour development, and which leads to locoregional or distant tumour progression in later stages of the disease. Recent studies were done on DNA content, proliferative activity, abnormalities of oncogenes or tumour-suppressor genes, the objective being to determine whether these factors could serve as precise indicators of the clinical course (Korenaga et al., 1990; Mizutani et al., 1993; Joypaul et al., 1994) . A feature common to all these prognostic factors is that, from excised tumour material, one attempts to extrapolate to the malignant potential of occult cells that may possibly be present in the patient. Diagnostic techniques currently available are not sufficiently sensitive to detect unicellular or oligocellular micrometastasis.
Monoclonal antibodies used in conjunction with immunocytochemical procedures are potent probes to identify individual tumour cells in bone marrow aspirates from patients with various cancers (Schlimok and Riethmuller, 1990a) . As cytokeratin proteins are essential constituents of the cytoskeleton of both normal and malignant epithelial cells, they can serve as reliable markers for the epithelial origin of cells (Debus et al., 1984) . In particular, the use of a monoclonal antibody against the cytokeratin component no. 18 expressed by all tumour cells derived from simple epithelia facilitates identification of 1 in 105 epithelial tumour cells in bone marrow of patients with colorectal, gastric, mammary, lung and prostate cancers (Mansi et al., 1987; Schlimok and Riethmiiller, 1990a; Lindemann et al., 1992; Pantel et al., 1993a; Oberneder et al., 1994) . Schlimok and Riethmuller (1990a) (Figure 1 ). The alkaline phosphatase-stained cells in cytocentrifuge preparations appeared as red single or clustered cells, and were present at a frequency of 104-10 nucleated cells. These cells were de-stained and confirmed as cancer cells by Papanicolaou staining. The positive findings did not depend on sex, age or location of the tumour. In cases of cytokeratin-positive cells, undifferentiated tissue type was more frequent and the depth of invasion was more prominent. Lymphatic and vascular involvement and metastasis to lymph nodes, peritoneal dissemination and liver metastasis showed no relation with the presence of micrometastasis in the bone marrow (Table I) .
Relation between the presence of micrometastasis and p53 staining
We determined the relation between the detection of cytokeratin-positive cells in the bone marrow and abnormal p53 staining in the primary lesion. The positive rate of p53 was 25.8% (8/31) for cytokeratin-negative patients and 26.6% (4/15) for cytokeratin-positive ones, with no significant difference (Table II) .
Relation between the presence of micrometastasis and the RB staining The labelling index of RB staining of primary lesion was determined between the cytokeratin-negative and -positive groups. RB labelling index was 56.5 ± 25.6% for the cytokeratin-negative group and 66.9 ± 20.5% for the cytokeratin-positive group, with no significant difference (Table  III) .
Relation between the presence of micrometastasis and the MIB-I staining The labelling index of MIB-1 staining of primary lesion was determined between the cytokeratin-negative and -positive groups. MIB-1 staining was 60.3 ± 20.9% for the cytokeratin-negative group and 58.9 ± 20.5% for the cytokeratinpositive group, with no significant difference (Table III) .
Discussion
Even after a curative resection there can be recurrences in patients with advanced or even early gastric cancer (Ichiyoshi et al., 1990; Maehara et al., 1992) . A highly sensitive method is needed to predict metastatic potential and clinical outcome and to design pertinent treatments. Gastric cancer markers may provide prognostic information independent of and complementary to conventional parameters, including growth potential, oncogenes, tumour-suppressor genes and DNA flow cytometry, as well as other growth factors (Korenaga et al., 1990; Mitzutani et al., 1993; Joypaul et al., 1994) . The common characteristic of these prognostic factors is that they correlate a property of the primary tumour with the subsequent outcome.
The method we have described here relates to an aspect of the actual behaviour of the tumour, microscopic dissemination of cancer cells in the bone marrow. Cytokeratin expression is conserved in nearly all normal epithelial cells as well as in primary and metastatic carcinoma cells (Debus et al., 1984) and is absent in haematopoietic and lymphatic cells. As cytokeratin-positive cells were not detected in bone marrow, they are suitable to detect micrometastases present in the marrow (Schlimok and Riethmiiller, 1990a (Yonemura et al., 1993; Joypaul et al., 1994) . MIB-1 reacts with a nuclear non-histone protein (Ki-67 antigen) in all active parts of the cell cycle and the level of labelling index relates to lymphatic and vascular progression (Cattoretti et al., 1992) . As similar distributions of markers of tumour malignancy and proliferation were found on the primary lesion, irrespective of the presence of cytokeratinpositive cells in bone marrow, characteristics of the metastasis to bone marrow and the outgrowth of tumour cells into visible metastases need to be clarified.
Overt bone or skeleton metastases are rare in patients with gastric cancer, however, bone marrow is distinctly more often involved than expected from the clinical findings (Koga et al., 1987; Lindemann et al., 1992) . The apparent discrepancy between clinically rare bone metastases and the marrow micrometastases frequently detected by immunocytochemistry may be explained by a reduced proliferative behaviour of the cells and often invoked state of dormancy (Schlimok et al., 1990b; Cote et al., 1991) . The capacity of the tumour cells to proliferate in the bone marrow and to manifest metastasis depends on the microenvironment. The presence of disseminated cells in bone marrow could also indicate that cancer cells have reached the peritoneum, liver or lung (Lindemann et al., 1992) . Therefore, these patients may have complications arising from peritoneal dissemination or liver metastasis with no manifest metastasis in the bone marrow (Maehara et al., 1991; Moriguchi et al., 1992) .
Cytokeratin-positive cells in the bone marrow of gastric cancer patients may serve as valid indicators of the intrinsic metastatic activity of an individual tumour. Patients presenting with disseminated cytokeratin-positive cells at the time of primary surgery have to be closely followed and the possible presence of distant metastasis should always be a concern for attending physicians.
